RMD-010

RMD-010 is a discovery-stage gene therapy candidate being developed by Remedium Technologies (also known as Remedium Bio) for the treatment of endocrine disorders, specifically targeting obesity and type 2 diabetes. The therapy utilizes the proprietary Prometheus™ platform, which is designed to provide adjustable, regulated expression of a therapeutic transgene. RMD-010 can be delivered using either adeno-associated virus (AAV) or lipid nanoparticle (LNP) vectors. While the specific molecular target for RMD-010 has not been publicly disclosed, the platform's goal is to enable the continuous production of therapeutic proteins following a single administration, potentially offering a more effective and convenient alternative to frequent protein injections.